Improving the outcomes of medical or surgical castration for men with prostate cancer has been an elusive goal since the approach was first reported in the 1940s.
1 However, this situation changed at the annual American Society of Clinical Oncology meeting in 2014, when results reported from the ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease (CHAARTED) showed that addition of six cycles of docetaxel to standard of care (testosterone lowering hormone therapy) prolonged the survival of men with metastatic disease at the time of diagnosis relative to treatment with hormones alone.
2, 3 The result contrasted with a trial of similar design, GETUG-AFU 15, that did not show a survival benefit.
4/.../
No comments:
Post a Comment